Dissolution Testing: In Vitro Characterizatio of Oral Controlled Release Dosage Forms

Oral Controlled Release Formulation Design and Drug Delivery: Theory to Practice

Volumn , Issue , 2010, Pages 245-256

  Guo, Michele Xuemei ^a  

^a WYETH RESEARCH   (United States)

Author keywords

Dissolution testing in vitro characterization of oral controlled release dosage forms; Dissolution testing, integral part of pharmaceutical development and batch quality assurance for product safety and efficacy; Dissolution, vital part of pharmaceutical development for controlled release formulation

Indexed keywords

EID: 84885536012     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1002/9780470640487.ch15     Document Type: Chapter

References (54)

1. Guidance for Industry. SUPAC-MR: Modified Release Solid Oral Dosage Forms, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD, September 1997.
2. Guidance for Industry. Extended Release Oral Dosage Forms: Development, Evaluation and Application of In- Vitro/In-Vivo correlations, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD, September 1997.
3. Colombo P, Bettini R, Santi P, Peppas NA. Swellable matrices for controlled drug delivery: gel-layer behavior, mechanisms and optimal performance. Pharm. Sci. Technol. Today 2000; 3(6):198-204.
4. Li H, Hardy RJ, Gu X. Effect of drug solubility on polymer hydration and drug dissolution from polyethylene oxide (PEO) matrix tablets. AAPS PharmSciTech 2008;9(2): 437-443.
5. Zhang F, McGinity JW. Properties of sustained-release tablets prepared by hot-melt extrusion. Pharm. Dev. Technol. 1999; 4(2):241-250.
6. Shah N, Zhang GH. Prediction of drug release from hydroxypropyl methylcellulose (HPMC) matrices: effect of polymer concentration. Pharm. Res. 1993;10(12):1693-1695.
7. Mockeland JE, Lippold BC. Zero-order drug release from hydrocolloid matrices. J. Pharm. Sci. 1993;10(7):1066-1070.
8. Dressman JB, Amidon G, Reppas C, Shah VP. Dissolution testing as a prognostic tool for oral drug absorption: immediate release dosage forms. Pharm. Res. 1998;15(1):11-22.
9. Amiden GL, Lennernas H, Shah VP, Crison JR. A theoretical basis for a biopharmaceutics drug classification: the correlation of in vitro drug product dissolution and in vivo bioavailability. Pharm. Res. 1995;12(3):413-420.
10. Guidance for Industry. Dissolution Testing of Immediate Release Solid Oral Dosage Forms, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD, August 1997.
11. Guidance for Industry. Waiver for In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Form Based on a Biopharmaceutics Classification System, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER), Rockville, MD, August 2000.
12. Jamzad S, Fassihi R. Role of surfactant and pH on dissolution properties of fenofibrate and glipizide-a technical note. AAPS PharmSciTech 2006;7(2):E1-E6.
13. Battchar SN Wesley JA Fioritto A, Martin PJ Babu SR. Dissolution testing of a poorly soluble compound using the flow-through cell apparatus. Int. J. Pharm. 2002; 236:135-143.
14. Papp R, Luk P, Mullett WM Kwong E, Debnath S, Thibert R. Development of a discriminating in vitro dissolution method for a poorly soluble NO-donating selective cyclooxygenase-2 inhibitor. J. Pharm. Biomed. Anal. 2008;47:16-22.
15. Rasenack N, Muller BW. Dissolution rate enhancement by in situ micronization of poorly water-soluble drugs. Pharm. Res. 2002;19(12):1894-1900.
16. Machin L, Sartnurak S, Thomas I, Moore S. The impact of low levels of amorphous material (<5%) on the blending characteristics of a direct compression formulation. Int. J. Pharm. 2002;231:213-226.
17. Feeley JC, York P, Sumby BS, Dicks H. Determination of surface properties and flow characteristics of salbutamol sulphate, before and after micronisation. Int. J. Pharm. 1998; 172:89-96.
18. Kaqashima Y. Nanoparticulate systems for improved drug delivery. Adv. Drug Deliv. Rev. 2001;47(1):1-2.
19. Donato EM, Martins LA, Froehlich PE, Bergold AM. Development and validation of dissolution test for lopinavir, a poorly water-soluble drug, in soft gel capsules, based on in vivo data. J. Pharm. Biomed. Anal. 2008;47:547-552.
20. Borst I, Ugwu S, Beckett AH.New and extended applications for USP drug release apparatus 3, Dissolution Technologies, February 1997, pp. 11-18.
21. Joshi A, Pund S, Nivsarkar M, Vasu K, Shishoo C. Dissolution test for site-specific release ionized pellets in USP apparatus (reciprocating cylinder): optimization using response surface methodology. Eur. J. Pharm. Biopharm. 2008;69: 769-775.
22. Wong D, Larrabee S, Clifford K, Tremblay J, Friend DR. USP dissolution apparatus 3 (reciprocating cylinder) for screening of guar-based colonic delivery formulations. J. Control. Release 1997;47:173-179.
23. Li J, Yang L, Ferguson SM, Hudson TJ, Watanabe S, Katsuma M, Fix JA. In vitro evaluation of dissolution behavior for a colon-specific drug delivery system (CODES™) in multi-pH media using United States pharmacopoeia apparatus II and III. AAPS PharmSciTech 2002;3(4): article 33.
24. Cacace J, Reilly EE, Amann A. Comparison of the dissolution of metaxalone tablets (Skelaxin) using USP apparatus 2 and 3. AAPS PharmSciTech 2004;5(1): article 6.
25. Missaghi S, Fassihi R. Release characteristic of dimenhydrinate from an eroding and swelling matrix: selection of appropriate dissolution apparatus. Int. J. Pharm. 2005;293:35-42.
26. Perng CY, Kearney AS, Palepu NR, Smith BR, Azzarano LM. Assessment of oral availability enhancing approaches of SB-using flow through cell dissolution testing as one of the screens. Int. J. Pharm. 2003;250:147-156.
27. Jinno J, et al. In-vitro-in-vivo correlation of wet milled tablet of poorly soluble cilostazol. J. Control. Release 2008;130(1): 29-37.
28. Cammarn SR, Sakr A. Predicting of dissolution though hydrodynamics: salicylic acid tablets in flowthrough cell dissolution. Int. J. Pharm. 2000;201:199-209.
29. Motz SA, Schaefer UF, Balbach S, Eichinger T, Lehr C-M. Permeability assessment for solid oral drug formulations based on Caco-2 monolayer in combination with a flow through dissolution cell. Eur. J. Pharm. Biopharm. 2007;66:286-295.
30. Khamanga SMM, Walker RB. The effects of buffer molarity, agitation rate, and mesh size on verapamil release from modified- release mini-tablets using USP apparatus 3, Dissolution Technologies, May 2007, pp. 19-23.
31. Bai G, Armenante PM. Velocity distribution and shear rate variability resulting from changes in the impeller location in the USP dissolution testing apparatus II. Pharm. Res. 2008; 25(2):320-336.
32. Kamba M, Seta Y, Takeda N, Hamaura T, Kusai A, Nakane H, Nishimura K. Measurement of agitation force in dissolution test and mechanical destructive force in disintegration test. Int. J. Pharm. 2003;250:99-109.
33. Underwood FL, Cadwallader DE. Effects of various hydrodynamic conditions on dissolution rate determinations. J. Pharm. Sci. 1976;65:697-700.
34. Mirza T, Joshi Y, Liu Q, Vivilecchia R. Evaluation of dissolution hydrodynamics in the USP, Peak™ and flat-bottom vessels using different solubility drugs. Dissolution Technologies 2005, 11-16.
35. Collins CC, Nair RR. Comparative evaluation of mixing dynamics in USP apparatus 2 using standard USP vessels and Peak™ vessels, Dissolution Technologies, May 1998, pp. 17-21.
36. Rohrs BR, Bruch-Clark DL Witt MJ, Stelzer DJ. USP dissolution apparatus 3 (reciprocating cylinder): instrument parameter effects on drug release from sustained release formulations. J. Pharm. Sci. 1995;84:922-926.
37. Sheng JJ, Kasim NA, Chandrasekharan R, Amidon GL. Solubilization and dissolution of insoluble weak acid, ketoprofen: effects of pH combined with surfactant. Eur. J. Pharm. Sci. 2006;29:306-314.
38. McNamara DP, Amidon GL. Reaction plane approach for estimating the effects of buffers on the dissolution rate of acidic drugs. J. Pharm. Sci. 1988;77:511-517.
39. Zhao F, Malayev V, Rao V, Hussain M. Effect of sodium lauryl sulfate in dissolution media on dissolution of hard gelatin capsule shells. Pharm. Res. 2004;21:144-148.
40. Mooney KG, Mintun MA, Himmelstein KJ, Stella VJ. Dissolution kinetics of carboxylic acids II: effect of buffers. J. Pharm. Sci. 1981;70:22-32.
41. Aunins JG, Southard MZ, Meyers RA, Himmelstein KJ, Stella VJ. Dissolution of carboxylic acids III: effect of polyionizable buffers. J. Pharm. Sci. 1985;74:1305-1316.
42. Ramtoola Z, Corrigan OI. Influence of he buffering capacity of the medium on the dissolution of he drug excipient mixtures. Drug Dev. Ind. Pharm. 1989;15:2359-2374.
43. McNamara DP, Whitney KM, Goss SL. Use of a physiological bicarbonate buffer system for dissolution characterization of ionizable drugs. Pharm. Res. 2003;20:1641-1646.
44. Galia E, Nicolaides E, Horter D, Lobenberg R, Reppas C, Dressman JB. Evaluation of various dissolution media for predicting in vivo performance of class I and II drugs. Pharm. Res. 1998;15:698-705.
45. Lobenberg R, Kramer J, Shah VP, Amidon GL, Dressman JB. Dissolution testing as a prognostic tool for oral drug absorption: dissolution behavior of glibenclamide. Pharm. Res. 2000; 17(4):439-444.
46. Nicolaides E, Galia E, Efthymiopoulos C, Dressman JB, Reppas C. Forecasting in vivo performance of four low solubility drugs from their in vitro dissolution data. Pharm. Res. 1999; 16(12):1876-1882.
47. Dressman JB, Reppas C. In vitro-in vivo corrections for lipophilic, poorly water-soluble drugs. Eur. J. Pharm. Sci. 2000;11(2):S73-S80.
48. Nicolaides E, Symillides M, Dressman JB, Reppas C. Biorelevant dissolution testing to predict the plasma profile of lipophilic drugs after oral administration. Pharm. Res. 2001;18:380-388.
49. Jantratid E, Janssen N, Reppas C, Dressman JB. Dissolution media simulating conditions in the proximal human gastrointestinal tract: an update. Pharm. Res. 2008;25(7):1663-1676.
50. Lue BM, Nielsen FS, Magnussen T, Schou HM, Krisensen K, Jacobsen LO, Mullertz A. Using biorelevant dissolution to obtain IVIVC of solid dosage forms containing a poorlysoluble model compound. Eur. Pharm. Biopharm. 2008; 69:648-657.
51. Lu X, Lozano R, Shah P. In-situ dissolution testing using different UV fiber optic probes and instruments, Dissolution Technologies. November 2003 6-15.
52. Bynum K,Roinestad K, KassisA, Procreva J,Gehriein L, Cheng F, Palermo P.Analytical performance of a fiber optic probes dissolution system, Dissolution Technologies, November 2001, pp. 13-22.
53. Liu L,Fitzgerald G, Embry M, Cantu R, Pack B.Technical evaluation of a fiber-optic probe dissolution system, Dissolution Technologies, 2008, pp. 10-20.
54. U.S. Pharmacopoeia 31, Rockville, MD.